Delving into the Latest Updates on Birch pollen allergy vaccine(Anergis) with Synapse

Overview

Basic Info

Drug Type

Allergen extract

Synonyms

AllerT, AllerT-Birch

Target-

Action

modulators

Mechanism

Immunomodulators

Therapeutic Areas

Immune System DiseasesInfectious DiseasesEye Diseases+ [2]

Active Indication-

Inactive Indication

Allergic rhinoconjunctivitisAnaphylaxisRhinitis, Allergic+ [2]

Originator Organization

University of Lausanne

Active Organization-

Inactive Organization

Anergis SA

License Organization

Anergis SA

Mymetics Corp.

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

The purpose of this study is to find the optimal dose of AllerT that should be used to treat moderate to severe allergies due to birch tree pollen.
There are 4 treatment groups in this study; 3 treatment groups will receive AllerT at different doses and 1 treatment group will receive placebo.
This study will also assess the effectiveness and safety of AllerT compared to placebo in relieving allergy symptoms.

Start Date01 Oct 2014

Sponsor / Collaborator

Anergis SA

[+1]

100 Clinical Results associated with Birch pollen allergy vaccine(Anergis)

Login to view more data

100 Translational Medicine associated with Birch pollen allergy vaccine(Anergis)

Login to view more data

100 Patents (Medical) associated with Birch pollen allergy vaccine(Anergis)

Login to view more data

1

Literatures (Medical) associated with Birch pollen allergy vaccine(Anergis)

01 Jul 2014·The Journal of allergy and clinical immunologyQ1 · MEDICINE

Safety and immunogenicity of immunotherapy with Bet v 1–derived contiguous overlapping peptides

Q1 · MEDICINE

Letter

Author: Audran, Régine ; Thierry, Anne-Christine ; Barbier, Nathalie ; Reymond, Christophe ; Spertini, François ; Charlon, Vincent ; Boudousquié, Caroline ; Pellaton, Céline ; Perrin, Yannick

This article presents the safety and immunogenicity of immunotherapy with Bet v 1-derived contiguous overlapping peptides.Clin. trial showed that 5 injections of AllerT administered over 2 mo elicit a strong immune response in the range of that observed after 50 injections and 3 years with other allergens and led to long-term immunol. memory were presented.Changes from baseline in Bet v 1-specific IgG4 and IgE levels were determined, and the ratios of normalized anti-Bet v 1 IgG4 and anti-Bet v 1 IgE over baseline were shown graphically.On an exploratory basis, P values for the median fold difference in IgG4 and IgE levels between AllerT- and placebo-treated patients were determined by using the nonparametric, nonpaired Mann-Whitney test.

100 Deals associated with Birch pollen allergy vaccine(Anergis)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Allergic rhinoconjunctivitis	Phase 2	Canada	Anergis SA	01 Oct 2014
Rhinitis, Allergic	Phase 2	Canada	Anergis SA	01 Oct 2014
Rhinitis, Allergic, Seasonal	Phase 2	Denmark	Anergis SA	01 Oct 2012
Rhinitis, Allergic, Seasonal	Phase 2	France	Anergis SA	01 Oct 2012
Rhinitis, Allergic, Seasonal	Phase 2	Latvia	Anergis SA	01 Oct 2012
Rhinitis, Allergic, Seasonal	Phase 2	Lithuania	Anergis SA	01 Oct 2012
Rhinitis, Allergic, Seasonal	Phase 2	Poland	Anergis SA	01 Oct 2012
Rhinitis, Allergic, Seasonal	Phase 2	Sweden	Anergis SA	01 Oct 2012
Rhinitis, Allergic, Seasonal	Phase 2	Switzerland	Anergis SA	01 Oct 2012
Rhinoconjunctivitis	Phase 2	Denmark	Anergis SA	01 Oct 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01720251 (CTgov)	Phase 2	Rhinoconjunctivitis \| Rhinitis, Allergic, Seasonal	240	placebo (Placebo)	hsddprpsch(xhvwhtjdiu) = ydvnaicxhh zkgangkera (spowpnaomf, 0.603) View more	-	13 Apr 2015
				AllerT low dose (AllerT Low Dose)	hsddprpsch(xhvwhtjdiu) = ycoupwzwoo zkgangkera (spowpnaomf, 0.530)
AAAAI2014	Phase 2	Anaphylaxis IgG4 \| IgE	239	50μg COPs in Aluminum hydroxide	hzrjxuxtpo(uvfivcxvod) = 4 grade 3 systemic allergic reactions (WAO grading) that occurred more than 30 min after injection (total 769 injections of active compound) xjdmirqzty (tbtgznxnya )	Positive	01 Feb 2014
				100μg COPs in Aluminum hydroxide

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data